Timothée Olivier, MD
@Timothee_MD
Followers
3K
Following
3K
Media
437
Statuses
2K
Oncology (sarcoma, H&N, CUP). EBM, Health Policy @HUG_ge (Geneva), @vkprasadlab (UCSF). Geneva Ethics Committee. Co-EiC ESMO Rare Cancers. No COI. Views mine.
Genève, Suisse
Joined December 2021
"Are fears of rising cancer in young adults exaggerated?" 👉Find the answer in this unique video! So great to have @AdeAdamson for a live talk, followed by a fascinating Q&A with @vkprasadlab core members! Thanks, Ade 🙏 Congrats to @vrpatel97 and Gil Welch who co-authored
0
4
15
Reduce Toxicity and Save Money: The Paper and Website to Bookmark for Alternative Dosing in Oncology! https://t.co/WPLd9gtqQ2 via @Timothee_MD @Maherjane @DrMarkLythgoe
theoncologyshot.com
The website to boomark: https://oncdoc.org/
0
3
3
@Timothee_MD @vkprasadlab nice concept, aligns with our work on PFSratio, check it out https://t.co/91mDnCP1Cy Manuscript coming soon!
github.com
PROPHETS: a R package to exploit PROgression-free survival ratio as primary endpoint in PHasE 2 TrialS in oncology - fedenichetti/prophets_package
1
1
2
Lectura muy recomendable. Hay que dimensionar los efectos. En caso de NATALEE, hay que tratar a 22 pacientes durante 3 años y solo una de ellas evitará el evento de progresión o muerte (la mayor parte progresión). Dicho de otra manera, 21 no se beneficiarán ¿Qué coste tiene esto?
#ESMO25 MonarchE and NATALEE trials: 2 years of adjuvant abemaciclib or 3 years of adjuvant ribociclib. With nearly 40% of patients newly diagnosed with breast cancer potentially eligible, the stakes are high. Now MonarchE reported a survival benefit. See my take here:
0
2
7
In uncontrolled settings, is the observed benefit due to the drug or to indolent tumour biology? One way to answer this question is the Iceberg Plot, a visual I conceived and we published soon after I joined the @vkprasadlab Read more about it! https://t.co/F8WgolAOJg
5
15
48
Oral cancer drugs may cause significant side effects and come with high costs. Can we reduce both without compromising efficacy? I cover a key new publication exploring alternative dosing strategies in oncology — definitely one to bookmark! See here: https://t.co/YTwdegZpCO +
3
5
14
What is evidence-based diagnosis? AKA Bayesian clinical reasoning Watch my 2 minute pitch for why doctors should care
7
25
92
3/ @Timothee_MD on the MonarchE and NATALEE trials: https://t.co/ji6BbI1i89
#ESMO25 MonarchE and NATALEE trials: 2 years of adjuvant abemaciclib or 3 years of adjuvant ribociclib. With nearly 40% of patients newly diagnosed with breast cancer potentially eligible, the stakes are high. Now MonarchE reported a survival benefit. See my take here:
1
1
4
Food for thought on adj CDK4/6i
#ESMO25 MonarchE and NATALEE trials: 2 years of adjuvant abemaciclib or 3 years of adjuvant ribociclib. With nearly 40% of patients newly diagnosed with breast cancer potentially eligible, the stakes are high. Now MonarchE reported a survival benefit. See my take here:
0
1
3
Nice words from Jeremy Long about my new "The Oncology Shot" letter.🙏 Subscribe for free for regular and unique content.
0
2
10
#ESMO25 MonarchE and NATALEE trials: 2 years of adjuvant abemaciclib or 3 years of adjuvant ribociclib. With nearly 40% of patients newly diagnosed with breast cancer potentially eligible, the stakes are high. Now MonarchE reported a survival benefit. See my take here:
4
7
37
Out in EJC: https://t.co/zgTfGmWlth "Potential Alternative Dosage Strategies for Patent-Protected Oral Cancer Drugs" Please bookmark this website: https://t.co/mBZZg5Zw6y and amplify! One of the best papers I’ve read recently—congratulations to the authors, Austin Wesevich,
0
1
10
@apolo_andrea @PGrivasMDPhD I got this key ASCO GU slide, alongside with detailed explanations, from @apolo_andrea , thank you so much 🙏 Everything I needed is there. Congrats again for the fair reporting provided in the @NEJM and for the effort in conducting the AMBASSADOR trial!
0
2
5
Check out our latest in @JAMAInternalMed: the rising incidence of early-onset cancer is largely an epidemic of diagnosis, not disease https://t.co/LOzK264eJf
3
14
38
The epidemic of cancer in young Americans is more apparent than real. Always fun working with @vrpatel97 and HGW, pushing back against a potentially harmful narrative.
Check out our latest in @JAMAInternalMed: the rising incidence of early-onset cancer is largely an epidemic of diagnosis, not disease https://t.co/LOzK264eJf
0
4
16
This table is from AMBASSADOR https://t.co/vO4uyokEIs Do we know how many patients received "any systemic" therapy ? (here 12 received radiation, but there might be overlap) Thanks a lot! @apolo_andrea @PGrivasMDPhD
1
1
8
‼️🆕 Just published in @JAMAOnc: Consensus guidelines for the use of #NGS in #sarcoma pts: 🤔Little data supporting routine, nonselective use 🔬💊Potential benefit in selected entities 🏥Sarcoma experts are critical 🧬BUT we need more molecular data! ▶️ https://t.co/FZoVvA5EMm
4
23
56
#ESMO25: Paradigm shifts are occurring in the management of metastatic mutated #NSCLC. Alfredo Addeo describes some of the innovative #TargetedTherapies and combinations that are improving patient outcomes. #ESMODailyReporter ➡️ https://t.co/BszCZt7hIm
#LungCancer
@Alfdoc2
0
5
14
“Solving Racial Inequalities in HLA-Restricted Therapies: Lessons from ESMO 2025.” While two ESMO studies show encouraging results, they also highlight the issue of HLA restriction in anti-cancer therapies. Check out my new post : https://t.co/hivJpZ4Ppv
0
1
14
It’s amusing when reporters and writers do not have access to FDA information on manufacturing and sterility violations — yet make calls from the peanut gallery.
58
77
513